in the vth mrc myelomatosis trial , patients treated with a combination of adriamycin , carmustine , cyclophosphamide and melphalan are living significantly longer than those treated with melphalan alone , and this survival advantage persists after correction for the most important prognostic factor , beta 2 microglobulin .
C0026764
myelomatosis
C0025241
melphalan